Anixa Biosciences develops and acquires patented technologies for the purposes of patent monetization and patent assertion.
Industries BiotechnologyFinanceMarket ResearchPharmaceuticalTherapeuticsHeadquarters Regions Greater New York Area, East Coast, Northeastern US Founded Date 1982 Founders Amit Kumar Operating Status Active Last Funding Type Grant Also Known As ITUS Corporation Legal Name CopyTele, Inc.
Stock Symbol NASDAQ:ANIX Company Type For Profit
Phone Number 6315495974
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which
uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.